We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II–III Esophageal Squamous Cell Carcinoma.
- Authors
Huiping Zhu; Xiaoling Lu; Jian Jiang; Jingfeng Lu; Xinchen Sun; Yun Zuo
- Abstract
Objective: This study was conducted to explore the appropriate radical radiation dose in concurrent chemoradiotherapy (CCRT) for patients with inoperable stage II–III esophageal squamous cell carcinoma (ESCC). Methods: This retrospective study included patients with esophageal cancer (EC) from the database of patients treated at the Affiliated Zhangjiagang Hospital of Soochow University (1/2015–12/2019). Overall survival (OS), progression-free survival (PFS), objective remission rate (ORR), first failure pattern, and toxicities were collected. Results: 112 patients treated with intensity-modulated radiation therapy (IMRT) combined with concurrent chemotherapy of nedaplatin-based regimens were included. Fifty-eight (51.8%) and 54 (48.2%) patients received 60 (HD) and 50.4 (LD) Gy of radiotherapy, respectively. The HD group showed superior OS and a trend for longer PFS compared with the LD group (median OS: 25.5 vs 17.5 months, P = .021; median PFS: 14.0 vs 10.5 months, P = .076). There were more patients with a complete remission (CR) in the HD group than in the LD group (P=.016). The treatment-related toxicities were generally acceptable, but HD radiotherapy would increase the incidence of grade ≥3 late radiotoxicity (22.4% vs 5.6%, P = .011). Conclusion: In nedaplatin-based CCRT for stage II–III ESCC, the radiotherapy dose of 60 Gy achieved a better prognosis.
- Subjects
PROGRESSION-free survival; SQUAMOUS cell carcinoma; RADIOTHERAPY; RADIOISOTOPE brachytherapy; RADIATION doses; OVERALL survival; CANCER chemotherapy
- Publication
Dose-Response, 2022, Vol 20, Issue 1, p1
- ISSN
1559-3258
- Publication type
Article
- DOI
10.1177/15593258221076720